Chemed (CHE)
(Delayed Data from NYSE)
$554.39 USD
+5.12 (0.93%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $554.63 +0.24 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$554.39 USD
+5.12 (0.93%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $554.63 +0.24 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth A Momentum B VGM
Zacks News
Omnicell (OMCL) Inks New Deal to Manage Controlled Substances
by Zacks Equity Research
Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
by Zacks Equity Research
Robust performance across the Roto-Rooter segment and sequential growth in VITAS admissions are driving the top line for Chemed (CHE).
IDEXX (IDXX) CAG Placement Grows Globally, LPD Disappoints
by Zacks Equity Research
IDEXX' (IDXX) global Reference Lab businesses are robust driven by high same-store volume growth with strong gains across testing categories.
Quidel (QDEL) Q3 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Quidel (QDEL) records a strong Q3 performance despite lower revenues from two of its product categories.
Allscripts' (MDRX) Q3 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.
Accuray (ARAY) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Accuray (ARAY) registers growth in both Service and Product revenues during fiscal Q1.
BD (BDX) Beats on Q4 Earnings and Revenues, FY22 View Issued
by Zacks Equity Research
Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal fourth quarter, driving up the overall top line.
Avanos Medical (AVNS) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) third-quarter 2021 results gains from strength in the Pain Management segment.
PacBio's (PACB) Q3 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q3 product revenues, led by robust consumable and instrument sales.
Chemed (CHE) Q3 Earnings Beat Estimates, Full-Year EPS View Up
by Zacks Equity Research
Chemed (CHE) reports better-than-expected earnings and revenues in the third-quarter 2021, with a solid performance by the Roto-Rooter segment driving the top line.
Chemed (CHE) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 13.45% and 1.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Chemed (CHE) Q3 Earnings Expected to Decline
by Zacks Equity Research
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Chemed (CHE) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Chemed (CHE) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Chemed (CHE) Up 1.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemed (CHE) Upgraded to Buy: Here's Why
by Zacks Equity Research
Chemed (CHE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks.com featured highlights include: Cathay General Bancorp, Bio-Rad Laboratories, Chemed Corp, Materialise and Arbor Realty Trust
by Zacks Equity Research
Zacks.com featured highlights include: Cathay General Bancorp, Bio-Rad Laboratories, Chemed Corp, Materialise and Arbor Realty Trust
5 Stocks to Buy as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like CATY, BIO, CHE, MTLS and ABR.
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) on strong segmental growth and raised Roto-Rooter and earnings guidance for 2021.
DaVita (DVA) Beats on Q2 Earnings, Raises 2021 EPS View
by Zacks Equity Research
DaVita's (DVA) strength in dialysis patient service revenues drives its Q2 top line.
PacBio's (PACB) Q2 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q2 product revenues, led by robust consumable sales.
CVS Health (CVS) Q2 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
CVS Health (CVS) Q2 adjusted EPS drops year over year on escalating costs and expenses which are putting pressure on margins.
Avanos Medical (AVNS) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) second-quarter 2021 results gains from strength in Pain Management segment.
Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.
AmerisourceBergen (ABC) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter results benefit from segmental growth.